http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Merck to present HIV pipeline data at AIDS 2026 conference
-
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
-
Merck's Keytruda meets PFS endpoint in endometrial cancer trial
-
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)
-
FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad
-
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
-
Merck reaches deal to expand HIV drug access via ADAP programs
-
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
-
FDA approves Merck's Keytruda combo with Trodelvy for TNBC
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS �
-
EU approves Merck's Keytruda plus Padcev for bladder cancer
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
-
Merck's tulisokibart meets Phase 3 endpoints in ulcerative colitis trial
-
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
-
FDA approves Merck's Capvaxive for children at higher pneumonia risk
-
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
-
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
-
FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Ce
-
Merck Animal Health to acquire poultry technology firm TARGAN
-
Merck Animal Health to Acquire TARGAN
-
Gilead and Merck announce successful HIV treatment trial results
-
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
-
Merck and Gilead discontinue lung cancer drug combination trial
-
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
-
MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
-
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
-
FDA grants breakthrough therapy designation to Merck's KRAS G12C inhibitor
-
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
-
Merck to Participate in the Jefferies Global Healthcare Conference
-
Merck Announces Third-Quarter 2026 Dividend
-
Merck receives EU committee approval recommendation for bladder cancer drug combo
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasiv
-
Merck endometrial cancer drug meets survival goals in phase 3 trial
-
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R
-
Merck to present oncology data across 25 cancer types at ASCO 2026
-
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
-
Merck publishes synthesis method for oral PCSK9 inhibitor in Science
-
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
-
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
-
Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
-
Merck completes $5.8 billion acquisition of Terns Pharmaceuticals
-
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
-
Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of
-
Merck clears HSR waiting period for $53 per share Terns acquisition
-
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
-
Merck and Google Cloud announce $1 billion AI partnership
-
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
-
FDA approves Merck's IDVYNSO for HIV-1 treatment switch
